WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "b7a15f61-ea61-40b3-9f21-08ac5521a15b"}, "_deposit": {"created_by": 18, "id": "55264", "owners": [18], "pid": {"revision_id": 0, "type": "depid", "value": "55264"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00055264", "sets": ["1779"]}, "author_link": ["91854", "108", "85791", "49"], "item_4_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-05-07", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "17", "bibliographicPageEnd": "1858", "bibliographicPageStart": "1839", "bibliographicVolumeNumber": "24", "bibliographic_titles": [{"bibliographic_title": "World Journal of Gastroenterology"}]}]}, "item_4_creator_33": {"attribute_name": "著者別表示", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "向田, 直史"}], "nameIdentifiers": [{"nameIdentifier": "49", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30182067", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30182067"}, {"nameIdentifier": "30182067", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=30182067"}, {"nameIdentifier": "30182067", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000030182067"}]}, {"creatorNames": [{"creatorName": "中本, 安成"}], "nameIdentifiers": [{"nameIdentifier": "108", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40293352", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40293352"}, {"nameIdentifier": "40293352", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000040293352"}]}]}, "item_4_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells (APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor immunity is frequently repressed at tumor sites. Malignantly transformed cells rarely survive the attack by the immune system, but cells that do survive change their phenotypes to reduce their immunogenicity. The resultant cells evade the attack by the immune system and form clinically discernible tumors. Tumor microenvironments simultaneously contain a wide variety of immune suppressive molecules and cells to dampen tumor immunity. Moreover, the liver microenvironment exhibits immune tolerance to reduce aberrant immune responses to massively-exposed antigens via the portal vein, and immune dysfunction is frequently associated with liver cirrhosis, which is widespread in hepatocellular carcinoma (HCC) patients. Immune therapy aims to reduce tumor burden, but it is also expected to prevent non-cancerous liver lesions from progressing to HCC, because HCC develops or recurs from noncancerous liver lesions with chronic inflammatory states and/or cirrhosis and these lesions cannot be cured and/or eradicated by local and/or systemic therapies. Nevertheless, cancer immune therapy should augment specific tumor immunity by using two distinct measures: enhancing the effector cell functions such as antigen presentation capacity of APCs and tumor cell killing capacity of cytotoxic cells, and reactivating the immune system in immune-suppressive tumor microenvironments. Here, we will summarize the current status and discuss the future perspective on immune therapy for HCC. © The Author(s) 2018.", "subitem_description_type": "Abstract"}]}, "item_4_description_22": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "Supported by (in part) Research Programs on the Innovative Development and Application for New Drugs for Hepatitis B (No. 17fk0310116h0001) from the Japan Agency for Medical Research and Development (AMED) and Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University.", "subitem_description_type": "Other"}]}, "item_4_description_5": {"attribute_name": "提供者所属", "attribute_value_mlt": [{"subitem_description": "金沢大学がん進展制御研究所", "subitem_description_type": "Other"}]}, "item_4_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.24517/00061539", "subitem_identifier_reg_type": "JaLC"}]}, "item_4_publisher_17": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "W J G Press / Baishideng Publishing Group Co"}]}, "item_4_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.3748/wjg.v24.i17.1839", "subitem_relation_type_select": "DOI"}}]}, "item_4_relation_28": {"attribute_name": "関連URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "https://www.wjgnet.com/1007-9327/full/v24/i17/1839.htm"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.wjgnet.com/1007-9327/full/v24/i17/1839.htm", "subitem_relation_type_select": "URI"}}, {"subitem_relation_name": [{"subitem_relation_name_text": "https://www.wjgnet.com/1007-9327/index.htm"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.wjgnet.com/1007-9327/index.htm", "subitem_relation_type_select": "URI"}}]}, "item_4_rights_23": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright © 2018 Authors."}]}, "item_4_source_id_11": {"attribute_name": "NCID", "attribute_value_mlt": [{"subitem_source_identifier": "AA12048247", "subitem_source_identifier_type": "NCID"}]}, "item_4_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1007-9327", "subitem_source_identifier_type": "ISSN"}]}, "item_4_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Mukaida, Naofumi"}], "nameIdentifiers": [{"nameIdentifier": "85791", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30182067", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30182067"}, {"nameIdentifier": "30182067", "nameIdentifierScheme": "金沢大学研究者情報", "nameIdentifierURI": "http://ridb.kanazawa-u.ac.jp/public/detail.php?kaken=30182067"}, {"nameIdentifier": "30182067", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000030182067"}]}, {"creatorNames": [{"creatorName": "Nakamoto, Yasunari"}], "nameIdentifiers": [{"nameIdentifier": "91854", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "40293352", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=40293352"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2021-03-26"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "CA-PR-MUKAIDA-N-24-1839.pdf", "filesize": [{"value": "1.5 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_11", "mimetype": "application/pdf", "size": 1500000.0, "url": {"label": "CA-PR-MUKAIDA-N-1839.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/55264/files/CA-PR-MUKAIDA-N-24-1839.pdf"}, "version_id": "24df559d-3343-4288-a851-0626acc79c31"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Chimeric antigen receptor T cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cytokine-induced killer cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Cytotoxic lymphocyte antigen-4", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Dendritic cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Myeloid-derived suppressor cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Natural killer cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Natural killer T cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "PD-ligand 1", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Peptide vaccineProgram death-1", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Regulatory T cell", "subitem_subject_scheme": "Other"}, {"subitem_subject": "T cell receptor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Tumor infiltrating lymphocyte", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Tumor-associated antigen", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma"}]}, "item_type_id": "4", "owner": "18", "path": ["1779"], "permalink_uri": "https://doi.org/10.24517/00061539", "pubdate": {"attribute_name": "公開日", "attribute_value": "2021-03-26"}, "publish_date": "2021-03-26", "publish_status": "0", "recid": "55264", "relation": {}, "relation_version_is_last": true, "title": ["Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma"], "weko_shared_id": -1}
Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma
https://doi.org/10.24517/00061539
https://doi.org/10.24517/000615397f4f1432-764e-4440-bf3f-98f190f0de7b
名前 / ファイル | ライセンス | アクション |
---|---|---|
CA-PR-MUKAIDA-N-1839.pdf (1.5 MB)
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2021-03-26 | |||||
タイトル | ||||||
タイトル | Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
ID登録 | ||||||
ID登録 | 10.24517/00061539 | |||||
ID登録タイプ | JaLC | |||||
著者 |
Mukaida, Naofumi
× Mukaida, Naofumi× Nakamoto, Yasunari |
|||||
著者別表示 |
向田, 直史
× 向田, 直史× 中本, 安成 |
|||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 金沢大学がん進展制御研究所 | |||||
書誌情報 |
World Journal of Gastroenterology 巻 24, 号 17, p. 1839-1858, 発行日 2018-05-07 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1007-9327 | |||||
NCID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA12048247 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.3748/wjg.v24.i17.1839 | |||||
出版者 | ||||||
出版者 | W J G Press / Baishideng Publishing Group Co | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Tumor immunity proceeds through multiple processes, which consist of antigen presentation by antigen presenting cells (APCs) to educate effector cells and destruction by the effector cytotoxic cells. However, tumor immunity is frequently repressed at tumor sites. Malignantly transformed cells rarely survive the attack by the immune system, but cells that do survive change their phenotypes to reduce their immunogenicity. The resultant cells evade the attack by the immune system and form clinically discernible tumors. Tumor microenvironments simultaneously contain a wide variety of immune suppressive molecules and cells to dampen tumor immunity. Moreover, the liver microenvironment exhibits immune tolerance to reduce aberrant immune responses to massively-exposed antigens via the portal vein, and immune dysfunction is frequently associated with liver cirrhosis, which is widespread in hepatocellular carcinoma (HCC) patients. Immune therapy aims to reduce tumor burden, but it is also expected to prevent non-cancerous liver lesions from progressing to HCC, because HCC develops or recurs from noncancerous liver lesions with chronic inflammatory states and/or cirrhosis and these lesions cannot be cured and/or eradicated by local and/or systemic therapies. Nevertheless, cancer immune therapy should augment specific tumor immunity by using two distinct measures: enhancing the effector cell functions such as antigen presentation capacity of APCs and tumor cell killing capacity of cytotoxic cells, and reactivating the immune system in immune-suppressive tumor microenvironments. Here, we will summarize the current status and discuss the future perspective on immune therapy for HCC. © The Author(s) 2018. | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Supported by (in part) Research Programs on the Innovative Development and Application for New Drugs for Hepatitis B (No. 17fk0310116h0001) from the Japan Agency for Medical Research and Development (AMED) and Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University. | |||||
権利 | ||||||
権利情報 | Copyright © 2018 Authors. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.wjgnet.com/1007-9327/full/v24/i17/1839.htm | |||||
関連名称 | https://www.wjgnet.com/1007-9327/full/v24/i17/1839.htm | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.wjgnet.com/1007-9327/index.htm | |||||
関連名称 | https://www.wjgnet.com/1007-9327/index.htm |